Cirrhosis of the liver is most commonly divided into four stages, though the answer depends on which staging system you’re looking at. The simplest and most widely used clinical framework splits cirrhosis into just two broad stages: compensated (no symptoms) and decompensated (symptoms present). A more detailed classification breaks it into four substages based on specific complications. And separate scoring systems like Child-Pugh and MELD measure severity on a continuous scale rather than in fixed stages.
The Four-Stage Clinical Model
The most frequently cited staging system divides cirrhosis into four stages based on the presence of two key complications: enlarged veins in the esophagus or stomach (called varices) and fluid buildup in the abdomen (called ascites). Varices develop when scarring forces blood to find alternate routes through the body, and ascites occurs when the liver can no longer produce enough protein to keep fluid in the bloodstream.
- Stage 1: No varices, no ascites. The liver is scarred but still functioning well enough that you have no symptoms.
- Stage 2: Varices have developed, but there is still no ascites or bleeding. You may still feel relatively normal.
- Stage 3: Ascites is present, with or without varices. This marks the transition to decompensated cirrhosis.
- Stage 4: Bleeding from varices, with or without ascites. This is the most dangerous stage and carries the highest short-term mortality risk.
The critical dividing line falls between stages 2 and 3. Once ascites, bleeding, jaundice (yellowing of the skin and eyes), or hepatic encephalopathy (confusion caused by toxin buildup in the brain) develops, cirrhosis is considered decompensated. That shift changes the outlook significantly.
Compensated vs. Decompensated Cirrhosis
The U.S. Department of Veterans Affairs and many hepatologists use a simpler two-stage system: compensated and decompensated. Compensated cirrhosis is the asymptomatic stage. Your liver is damaged, but it’s still handling its essential jobs well enough that you don’t experience major complications. Many people in this stage don’t even know they have cirrhosis. Median survival with compensated cirrhosis is approximately 9 to 12 years.
Decompensated cirrhosis is the symptomatic stage, defined by the appearance of one or more serious complications: ascites, jaundice, bleeding from varices, or hepatic encephalopathy. Survival drops substantially once decompensation occurs, and treatment shifts from managing the underlying cause to controlling these complications and evaluating whether a liver transplant is needed.
Fibrosis Stages Before Cirrhosis
It’s worth noting that cirrhosis itself is actually the final stage of a longer process called liver fibrosis. The METAVIR scale, commonly used by pathologists, grades fibrosis from F0 to F4. F0 means no scarring at all, F1 is mild scarring around the liver’s portal tracts, F2 is scarring that extends further outward, F3 is bridging fibrosis where scar bands connect different parts of the liver, and F4 is full cirrhosis. So when people refer to “stage 4 liver disease,” they sometimes mean F4 on the METAVIR scale, which is the point at which cirrhosis has been established, not a stage within cirrhosis itself.
A non-invasive test called transient elastography (often known by the brand name FibroScan) can estimate your fibrosis stage by measuring liver stiffness. The threshold for cirrhosis varies by the underlying condition. For hepatitis C, a stiffness reading of 14.6 kilopascals or higher suggests cirrhosis. For hepatitis B with normal liver enzymes, the cutoff is around 12.0 kPa. For fatty liver disease, advanced fibrosis is considered at 9.8 kPa or above.
How Child-Pugh Scores Measure Severity
Once cirrhosis is established, the Child-Pugh scoring system is one of the most common tools for grading how well the liver is still functioning. It uses five measurements: bilirubin levels (a waste product the liver processes), albumin levels (a protein the liver makes), how well your blood clots, whether you have ascites, and whether you show signs of encephalopathy. Each factor gets 1 to 3 points, for a total between 5 and 15.
A score of 5 to 6 is Class A, meaning the liver is still functioning reasonably well despite cirrhosis. A score of 7 to 9 is Class B, indicating significant impairment. A score of 10 to 15 is Class C, the most severe category. These classes help predict outcomes and guide treatment decisions, particularly around surgery. Someone with Class A cirrhosis can generally tolerate procedures that would be far too risky for someone with Class C.
MELD Scores and Transplant Priority
The MELD score (Model for End-Stage Liver Disease) serves a different purpose: it estimates your risk of dying from liver disease within the next 90 days, and it determines your priority on the transplant waiting list. Rather than placing you in a stage, it produces a number based on blood tests measuring clotting ability, bilirubin, kidney function (creatinine), and blood sodium levels.
The 90-day mortality risk rises steeply with the score. A MELD score below 9 carries roughly a 1.9% risk. Between 10 and 19, that risk climbs to 6%. At 20 to 29, it reaches nearly 20%. A score of 30 to 39 means a 52.6% risk of death within three months, and above 40, the risk is 71.3%. Higher scores move you up the transplant list because the need is more urgent.
Can Early Cirrhosis Be Reversed?
One of the more hopeful findings in liver research is that fibrosis, and even early cirrhosis, can sometimes reverse if the underlying cause is eliminated. Early-stage scarring that hasn’t yet become heavily cross-linked has a genuine capacity to heal. The liver is unusual among organs in this respect.
The evidence is strongest for viral hepatitis. In a five-year study of patients with hepatitis B treated with antiviral therapy, 74% improved enough on biopsy that they were no longer classified as cirrhotic. For hepatitis C, 82% of patients who achieved a sustained cure after treatment showed decreased fibrosis scores over five years. In autoimmune hepatitis, 53% of treated patients saw fibrosis improve over about five years of follow-up. Even in hereditary iron overload (hemochromatosis), 35% of patients with established cirrhosis showed fibrosis regression after treatment to reduce iron levels.
For alcohol-related cirrhosis, stopping drinking is the single most important factor. Abstinence within a month of diagnosis is associated with significantly better long-term survival. The liver won’t fully regenerate in advanced cases, but halting the damage gives it room to partially recover and prevents the slide toward decompensation.
The key takeaway is that “cirrhosis” is not a single, fixed endpoint. It spans a wide range, from a scarred but functional liver with years of stable life ahead, to organ failure requiring transplant. Where you fall on that spectrum depends on the cause, how early it’s caught, and whether the underlying damage can be stopped.